AAD: Concerns Noted Relating to Use of AI Dermatology Apps
By Elana Gotkine HealthDay Reporter
FRIDAY, March 8, 2024 -- There are notable concerns relating to the use of currently available artificial intelligence (AI) dermatology mobile applications (apps), according to a study published online March 7 in JAMA Dermatology to coincide with the annual meeting of the American Academy of Dermatology, held from March 8 to 10 in San Diego.
Shannon Wongvibulsin, M.D., Ph.D., from the David Geffen School of Medicine at the University of California in Los Angeles, and colleagues conducted a scoping review to identify and characterize current English-language AI dermatology mobile apps available for download.
A total of 909 apps were identified initially; after removal of duplicates, 391 apps remained. A further 350 apps were excluded on subsequent review, yielding 41 apps available for detailed analysis. The researchers identified several concerning aspects relating to AI apps in dermatology. None of the apps were approved by the U.S. Food and Drug Administration; disclaimers for lack of regulatory approval were included in only two apps. The apps lacked supporting evidence, input from clinicians and/or dermatologists, and transparency in terms of development of algorithms, data usage, and user privacy.
"The use of these apps has risks associated with a lack of consistent validation and transparent user communication," the authors write. "These findings are important to increase awareness of the current limitations and the need to further develop methods for creation of AI dermatology apps with effective regulation, validation, and standardized evaluation criteria."
One author disclosed ties to the pharmaceutical and dermatology industries and has a related patent pending.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Lebrikizumab Tied to Sustained Atopic Dermatitis Treatment Effect
TUESDAY, June 18, 2024 -- Lebrikizumab is associated with sustained effects for moderate-to-severe atopic dermatitis for up to week 52 following withdrawal of treatment, according...
1.5 Percent Ruxolitinib Cream Safe, Effective for Teens With Eczema
FRIDAY, May 31, 2024 -- Long-term intermittent use of ruxolitinib cream is well tolerated and provides disease control in adolescent patients with atopic dermatitis (AD)...
Parental E-Cigarette Use Linked to Increase in Pediatric Atopic Dermatitis
TUESDAY, May 28, 2024 -- Parental electronic cigarette use is associated with increased odds of pediatric atopic dermatitis (AD), according to a research letter published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.